Lupus anticoagulant - Revision history

ClaireLewis at 04:45, 1 October 2019

2019-10-01T04:45:18Z

← Older revision		Revision as of 04:45, 1 October 2019
Line 6:		Line 6:

	==Clinical Features==		==Clinical Features==
	*Recurrent arterial/[[venous thrombosis\|venous thromboembolism]]		*Recurrent [[arterial thrombosis\|arterial]]/[[venous thrombosis\|venous thromboembolism]]
	*Recurrent [[miscarriage\|fetal loss]]		*Recurrent [[miscarriage\|fetal loss]]

Line 23:		Line 23:

	===Pregnancy===		===Pregnancy===
	''Miscarriage is common''		''[[Miscarriage]] is common''
	*Prophylaxis for most women		*Prophylaxis for most women
	*Patients with pregnancy loss		*Patients with pregnancy loss
	**Prophylactic heparin and low-dose [[ASA]]		**Prophylactic [[heparin]] and low-dose [[ASA]]
	*Patients with history of thrombosis		*Patients with history of thrombosis
	**Therapeutic heparin		**Therapeutic [[heparin]]

	===Prophylaxis===		===Prophylaxis===
	*Eliminate risk factors (OCPs, smoking, hypertension and HL)		*Eliminate risk factors (OCPs, smoking, hypertension and HL)
	*Low-dose ASA		*Low-dose [[ASA]]

	==Disposition==		==Disposition==

2019-09-19T17:28:02Z

← Older revision		Revision as of 17:28, 19 September 2019
Line 1:		Line 1:
	==Background==		==Background==
	*Misnomer as it is a prothrombotic agent in-vivo (anticoagulant in-vitro in the lab)		*Misnomer as it is a prothrombotic agent in-vivo (anticoagulant in-vitro in the lab)
	*Most patients do not actually have SLE (small proportion develop disease), but SLE patients more likely to develop lupus anticoagulant		*Most patients do not actually have [[SLE]] (small proportion develop disease), but SLE patients more likely to develop lupus anticoagulant
	*Included in ~~Antiphospholipid~~ syndrome (APS), where there are directed antibodies against membrane anionic phospholipids, or their associated plasma proteins		*Included in [[antiphospholipid syndrome]] (APS), where there are directed antibodies against membrane anionic phospholipids, or their associated plasma proteins
	**Increases aPTT		**Increases aPTT
	*Leads to recurrent venous/arterial thrombosis and/or fetal loss

	==Clinical Features==		==Clinical Features==
			*Recurrent arterial/[[venous thrombosis\|venous thromboembolism]]
			*Recurrent [[miscarriage\|fetal loss]]

	==Differential Diagnosis==		==Differential Diagnosis==

2017-07-24T01:12:48Z

Text replacement - "==References== " to "==References== <references/> "

2016-07-30T11:32:46Z

Text replacement - "HTN" to "hypertension"

← Older revision		Revision as of 11:32, 30 July 2016
Line 30:		Line 30:

	===Prophylaxis===		===Prophylaxis===
	*Eliminate risk factors (OCPs, smoking, ~~HTN~~ and HL)		*Eliminate risk factors (OCPs, smoking, hypertension and HL)
	*Low-dose ASA		*Low-dose ASA

2016-07-22T11:40:24Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

2016-06-21T16:50:11Z

Text replacement - " pts" to " patients"

← Older revision		Revision as of 16:50, 21 June 2016
Line 1:		Line 1:
	==Background==		==Background==
	*Misnomer as it is a prothrombotic agent in-vivo (anticoagulant in-vitro in the lab)		*Misnomer as it is a prothrombotic agent in-vivo (anticoagulant in-vitro in the lab)
	*Most ~~pts~~ do not actually have SLE (small proportion develop disease), but SLE ~~pts~~ more likely to develop lupus anticoagulant		*Most patients do not actually have SLE (small proportion develop disease), but SLE patients more likely to develop lupus anticoagulant
	*Included in Antiphospholipid syndrome (APS), where there are directed antibodies against membrane anionic phospholipids, or their associated plasma proteins		*Included in Antiphospholipid syndrome (APS), where there are directed antibodies against membrane anionic phospholipids, or their associated plasma proteins
	**Increases aPTT		**Increases aPTT

2015-06-10T13:04:11Z

Management

← Older revision		Revision as of 13:04, 10 June 2015
Line 14:		Line 14:

	==Management==		==Management==
	*Thrombosis (~~ie Extremity~~ phlebitis or dural sinus vein thrombosis)		*Thrombosis (e.g. extremity [[phlebitis]] or dural [[sinus vein thrombosis]])
	**Heparin IV/SQ followed by warfarin +/- ASA		**[[Heparin]] IV/SQ followed by [[warfarin]] +/- [[ASA]]
	**Goal INR		**Goal INR
	***Venous 2.0-3.0		***Venous 2.0-3.0
Line 25:		Line 25:
	*Prophylaxis for most women		*Prophylaxis for most women
	*Patients with pregnancy loss		*Patients with pregnancy loss
	**Prophylactic heparin and low-dose ASA		**Prophylactic heparin and low-dose [[ASA]]
	*Patients with history of thrombosis		*Patients with history of thrombosis
	**Therapeutic heparin		**Therapeutic heparin

2015-06-10T13:03:34Z

Management

← Older revision		Revision as of 13:03, 10 June 2015
Line 14:		Line 14:

	==Management==		==Management==
	~~#PPx~~		*Thrombosis (ie Extremity phlebitis or dural sinus vein thrombosis)
	~~##Eliminate risk factors (OCPs, smoking, HTN and HL)~~		**Heparin IV/SQ followed by warfarin +/- ASA
	~~##Low-dose ASA~~		**Goal INR
	#Thrombosis (ie Extremity phlebitis or dural sinus vein thrombosis)		***Venous 2.0-3.0
	##Heparin IV/SQ followed by warfarin +/- ASA		***Arterial 3.0
	##Goal INR		***Recurrent 3.0-4.0
	~~###~~Venous 2.0-3.0
	~~###~~Arterial 3.0		===Pregnancy===
	~~###~~Recurrent 3.0-4.0		''Miscarriage is common''
	~~#OB -~~ Miscarriage is common		*Prophylaxis for most women
	~~##PPx~~ for most women		*Patients with pregnancy loss
	~~##Pts~~ with pregnancy loss		**Prophylactic heparin and low-dose ASA
	~~###~~Prophylactic heparin and low-dose ASA		*Patients with history of thrombosis
	~~##Pts~~ with ~~h/o~~ thrombosis		**Therapeutic heparin
	~~###~~Therapeutic heparin
			===Prophylaxis===
			*Eliminate risk factors (OCPs, smoking, HTN and HL)
			*Low-dose ASA

	==Disposition==		==Disposition==

2015-06-10T13:01:14Z

← Older revision		Revision as of 13:01, 10 June 2015
Line 5:		Line 5:
	**Increases aPTT		**Increases aPTT
	*Leads to recurrent venous/arterial thrombosis and/or fetal loss		*Leads to recurrent venous/arterial thrombosis and/or fetal loss

			==Clinical Features==

			==Differential Diagnosis==
			{{Increased bleeding DDX}}

			==Diagnosis==

	==Management==		==Management==
Line 22:		Line 29:
	##Pts with h/o thrombosis		##Pts with h/o thrombosis
	###Therapeutic heparin		###Therapeutic heparin

			==Disposition==

	==See Also==		==See Also==
	*[[Coagulopathy (Main)]]		*[[Coagulopathy (Main)]]

	==~~Source~~==		==References==
	*Tintinalli
	*UpToDate

	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

2015-06-10T13:00:45Z

← Older revision	Revision as of 13:00, 10 June 2015
(No difference)